To compare the pharmacokinetics of two different concentrations, containing either 40 or 100 IU/ml of short-acting human insulin (Velasulin HM), intermediate-acting human insulin (Insulatard HM), or an insulin mixture (25% shortacting insulin, 75% intermediate-acting insulin; Mixtard HM), three rand
The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins
β Scribed by A. J. Francis; I. Hanning; K. G. M. M. Alberti
- Publisher
- Springer
- Year
- 1985
- Tongue
- English
- Weight
- 420 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0012-186X
No coin nor oath required. For personal study only.
β¦ Synopsis
The influence of moderate and low insulin antibody levels on insulin absorption and plasma free insulin profiles is uncertain. Two groups of six C-peptide negative diabetic patients, one with low (3.8 +/- 0.8 mu/l) and one with moderate (16.4 +/- 2.0 micrograms/l) serum insulin antibody levels, were studied. Subjects were given 0.3 U/kg neutral human or acid bovine soluble insulin subcutaneously in random order before breakfast on separate days. Moderate antibody levels significantly blunted the rise in plasma free insulin that followed injection of the human and bovine insulins (p less than 0.05). The rise in blood glucose after breakfast was significantly greater in patients with moderate antibody levels (p less than 0.05) and more marked following the bovine than the human insulin (p less than 0.05). Plasma free insulin, blood glucose and 3-hydroxybutyrate profiles suggest that acid bovine soluble insulin has a significantly more protracted action than neutral human insulin.
π SIMILAR VOLUMES
Since human immunoglobulins exert an insulinlike stimulatory effect on adipocyte lipogenesis at concentrations markedly lower than those found in vivo, and since human serum or plasma are only mildly stimulatory, we predicted that human serum probably contains an inhibitor of adipocyte lipogenesis.
## Abstract Previous reports have suggested an association between circulating IGFBPβ3 levels and the risk of premenopausal breast cancer, and a single nucleotide polymorphism (SNP) in the promoter region of IGFBPβ3 (nucleotide β202) was shown to influence transcription. There is prior evidence tha